Evidence map›Paper›PMID 34180967›Full record

ArticleJournal of Crohn's & colitis2021

Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.

John Gubatan, Samuel J S Rubin, Lawrence Bai, Yeneneh Haileselassie, Steven Levitte, Tatiana Balabanis, Akshar Patel, Arpita Sharma, Sidhartha R Sinha, Aida Habtezion

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04828031 (Vitamin D Regulation of α4β7+ B Cell Immunophenotypes and Mucosal Antibody Response to Commensal Gut Bacteria in Patients With Inflammatory Bowel Disease), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04828031 phase1completednot on this map

Vitamin D Regulation of α4β7+ B Cell Immunophenotypes and Mucosal Antibody Response to Commensal Gut Bacteria in Patients With Inflammatory Bowel Disease

TypeinterventionalSponsorStanford UniversityRan2021 to 2023Enrolled48ConditionsInflammatory Bowel Diseases, Ulcerative Colitis, Crohn DiseaseArmsVitamin D
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

John GubatanDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-6037-2883
Samuel J S RubinDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Lawrence BaiDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5617-9025
Yeneneh HaileselassieDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Steven LevitteDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Tatiana BalabanisDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Akshar PatelDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Arpita SharmaDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Sidhartha R SinhaDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Aida HabtezionDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · USChan Zuckerberg Initiative (United States) · US

Funding

Role and Regulation of colon Trafficking Novel G-Protein Coupled ReceptorsR01DK101119 · NIDDK · STANFORD UNIVERSITY · PI HABTEZION, AIDA · 2016 to 2019
$2.0M
Ann and Bill Swindells Charitable TrustNIDDK NIH HHS L30 DK126220NIDDK NIH HHS R01 DK101119NIH HHS NIH R01 DK101119
6 · The paper itself

Abstract

BACKGROUND AND

aimsVitamin D downregulates the in vitro expression of the gut-tropic integrin α4β7 on immune cells. The clinical relevance of this finding in patients with inflammatory bowel disease [IBD] is unclear. We tested the hypothesis that vitamin D is associated with α4β7 immunophenotypes and risk of vedolizumab [anti-α4β7] failure in IBD.

methodsWe performed single-cell immunophenotyping of peripheral and intestinal immune cells using mass cytometry [CyTOF] in vedolizumab-naïve patients with IBD [N = 48]. We analysed whole-genome mucosal gene expression [GSE73661] from GEMINI I and GEMINI long-term safety [LTS] to determine the association between vitamin D receptor [VDR] and integrin alpha-4 [ITGA4] and beta-7 [ITGB7] genes. We estimated the odds of vedolizumab failure with low pre-treatment vitamin D in a combined retrospective and prospective IBD cohort [N = 252] with logistic regression.

resultsImmunophenotyping revealed that higher 25[OH]D was associated with decreased α4β7+ peripheral blood mononuclear cells [R = -0.400, p <0.01] and α4β7+ intestinal leukocytes [R = -0.538, p = 0.03]. Serum 25[OH]D was inversely associated with α4β7+ peripheral B cells and natural killer [NK] cells and α4β7+ intestinal B cells, NK cells, monocytes, and macrophages. Mucosal expression of VDR was inversely associated with ITGA4 and ITGB7 expression. In multivariate analysis, 25[OH]D <25 ng/mL was associated with increased vedolizumab primary non-response during induction (odds ratio [OR] 26.10, 95% confidence interval [CI] 14.30-48.90, p <0.001) and failure at 1-year follow-up [OR 6.10, 95% CI 3.06-12.17, p <0.001].

conclusionsLow serum 25[OH]D is associated with α4β7+ immunophenotypes and predicts future vedolizumab failure in patients with IBD. PODCAST: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast.

Indexed as

AdultAntibodies, Monoclonal, HumanizedFemaleGastrointestinal AgentsHumansImmunophenotypingInflammatory Bowel DiseasesIntegrinsLeukocytes, MononuclearMaleTreatment FailureVitamin DAntibodies, Monoclonal, HumanizedGastrointestinal Agentsintegrin alpha4beta7IntegrinsvedolizumabVitamin Dclinical outcomesinflammatory bowel diseaseintegrinsvedolizumabVitamin D

Identifiers

PMID34180967
PMCPMC8684474
OpenAlexW3175219817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.